There isn't a lawmaker on Capitol Hill who's publicly taken a more conservative stance to biopharma's deal spree in China than Rep. John Moolenaar (R-MI), chairman of the House Select Committee on China. He's been the architect of recent legislative proposals that'd clamp down on deals there and also what data regulators can review. So how did this issue rise to his attention? And how committed is he to pressing the issue? Live from Endpoints’ China Biotech Debate: Washington, DC on September 15, 2026.
Podden och tillhörande omslagsbild på den här sidan tillhör
Endpoints News. Innehållet i podden är skapat av Endpoints News och inte av,
eller tillsammans med, Poddtoppen.
